ArticleFrontiers in oncology2020

Sintilimab, a PD-1 Inhibitor, Completely Reversed Rarely Refractory Hypofibrinogenemia in a Gastric Cancer Patient: A Case Report and Review of the Literature.

Shuzhen Ma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.